Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...

Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

BofA lowered the firm’s price target on Immunovant (IMVT) to $33 from $38 and keeps a Buy rating on the shares after yesterday’s topline data ...

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was ...

Fuels like kerosene can be produced in a climate-friendly way from CO2, water and green electricity using power-to-liquid ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...